Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JNJ-77242113 in biologic-naive active psoriatic arthritis
2023-509239-19-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Peptides
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: ACR20 response at Week 16. Planned start Apr 2025; status: authorised.
02
Drugs
icotrokinra
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2023-509239-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509239-19-00.